Doctor holding WATCHMAN device

WATCHMAN INCLUDED

in AF Management Guidelines

WATCHMAN is the Most Studied LAAC Device

Globally, WATCHMAN has been implanted in more than 70,000 patients and studied in more than 10 clinical studies. WATCHMAN is a safe and effective alternative to warfarin for stroke risk reduction and enables patients to discontinue OAC therapy. 

WATCHMAN’s inclusion in the updated guidelines is a result of years of clinical and real world evidence in support of the therapy as a safe and effective alternative to long-term warfarin use. 

See the Guidelines

Recommendation for Percutaneous Approaches to Occlude the LAA

Referenced studies that support the new recommendation are summarized in Online Data Supplement 4

COR LOE RECOMMENDATION
IIb
B-NR

1 Percutaneous LAA occlusion may be considered in patients with AF at increased risk of stroke who have contraindications to long-term anticoagulation (S4.4.1-1—S4.4.1-5).

NEW: Clinical trial data and FDA approval of the WATCHMAN device necessitated this recommendation.

The guidelines state that Percutaneous LAAO may be considered in patients with AF at increased risk of stroke who have contraindications to long-term anticoagulation.

Examples of patients with relative contraindications to anticoagulation include:

Patients with a history or risk of bleeding (including those with an active lifestyle or occupation)

Patients who are not adherent or compliant with their medications

Patients taking medications not compatible with anticoagulation